statistiche ricercatore

TANDA, MARIA LAURA PIERA

Distribuzione geografica

Continente	#
NA - Nord America	17.419
EU - Europa	7.470
AS - Asia	5.851
SA - Sud America	739
Continente sconosciuto - Info sul continente non disponibili	336
AF - Africa	135
OC - Oceania	16
AN - Antartide	1
Totale	31.967

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	17.027
IT - Italia	3.624
SG - Singapore	1.841
CN - Cina	1.382
UA - Ucraina	870
VN - Vietnam	781
HK - Hong Kong	629
SE - Svezia	622
BR - Brasile	575
DE - Germania	483
TR - Turchia	452
GB - Regno Unito	346
FI - Finlandia	330
IE - Irlanda	328
FR - Francia	283
BD - Bangladesh	278
RU - Federazione Russa	199
CA - Canada	192
IN - India	132
JP - Giappone	98
MX - Messico	89
PL - Polonia	65
AR - Argentina	56
NL - Olanda	51
NG - Nigeria	46
AT - Austria	43
CZ - Repubblica Ceca	38
ES - Italia	37
IQ - Iraq	34
ZA - Sudafrica	33
MY - Malesia	30
HN - Honduras	27
EC - Ecuador	26
CL - Cile	25
BE - Belgio	23
CH - Svizzera	23
ID - Indonesia	23
IL - Israele	21
PK - Pakistan	21
LT - Lituania	20
AE - Emirati Arabi Uniti	18
UZ - Uzbekistan	16
RO - Romania	15
SV - El Salvador	15
EU - Europa	14
VE - Venezuela	14
CO - Colombia	13
CR - Costa Rica	13
JM - Giamaica	13
NP - Nepal	11
PH - Filippine	11
SA - Arabia Saudita	10
TH - Thailandia	10
KR - Corea	9
MA - Marocco	9
MD - Moldavia	9
NI - Nicaragua	9
PE - Perù	9
PY - Paraguay	9
AU - Australia	8
GP - Guadalupe	8
GT - Guatemala	8
JO - Giordania	8
KE - Kenya	8
NZ - Nuova Zelanda	8
MT - Malta	7
TN - Tunisia	7
CW - ???statistics.table.value.countryCode.CW???	6
DZ - Algeria	6
EE - Estonia	6
EG - Egitto	6
KG - Kirghizistan	6
TT - Trinidad e Tobago	6
BG - Bulgaria	5
BY - Bielorussia	5
HU - Ungheria	5
PR - Porto Rico	5
PT - Portogallo	5
UY - Uruguay	5
AL - Albania	4
BO - Bolivia	4
ET - Etiopia	4
MK - Macedonia	4
TW - Taiwan	4
AZ - Azerbaigian	3
BA - Bosnia-Erzegovina	3
CI - Costa d'Avorio	3
DK - Danimarca	3
DO - Repubblica Dominicana	3
HR - Croazia	3
IR - Iran	3
KZ - Kazakistan	3
RS - Serbia	3
SC - Seychelles	3
SN - Senegal	3
SR - Suriname	3
BH - Bahrain	2
CG - Congo	2
GR - Grecia	2
KW - Kuwait	2
Totale	31.622

Salva come PNG Salva come JPEG

Città	#
Milan	2.150
Ashburn	1.671
Fairfield	1.411
San Jose	1.404
Dallas	1.300
Singapore	1.060
Woodbridge	832
Chandler	737
Jacksonville	685
Houston	682
Council Bluffs	632
Hong Kong	611
Seattle	574
Wilmington	527
Cambridge	451
Dearborn	367
Ann Arbor	354
Beijing	334
Nyköping	322
Dublin	308
Princeton	306
The Dalles	234
Los Angeles	233
Rome	227
New York	219
Izmir	216
Boardman	213
Chicago	200
Lauterbourg	187
Dong Ket	164
Santa Clara	153
Ho Chi Minh City	137
Helsinki	132
Hanoi	114
Como	105
San Diego	103
London	99
São Paulo	88
Orem	84
Phoenix	84
Tokyo	81
San Mateo	78
Munich	74
Buffalo	68
Guangzhou	66
Washington	64
Ogden	61
Montreal	56
San Francisco	55
Warsaw	55
Naples	54
Atlanta	53
Frankfurt am Main	53
North Bergen	53
Denver	50
Shanghai	50
Redmond	48
Brooklyn	47
Mexico City	47
Toronto	47
Chennai	46
Abuja	45
Hefei	41
Varese	37
Brno	33
Kunming	33
Manchester	33
Haiphong	27
Nuremberg	27
Düsseldorf	26
Salt Lake City	26
Vienna	26
Johannesburg	25
Poplar	25
Florence	24
Amsterdam	23
Boston	23
Stockholm	23
Tampa	23
Turku	23
Brussels	22
Norwalk	22
Nanjing	21
Turin	21
Las Vegas	20
Paris	20
Shenzhen	20
Austin	19
Cavaria con Premezzo	19
Tianjin	19
Charlotte	18
Da Nang	18
Hangzhou	18
Belo Horizonte	17
Berlin	17
Elk Grove Village	17
Jinan	17
Kuala Lumpur	17
Catania	16
Istanbul	15
Totale	21.832

Salva come PNG Salva come JPEG

Nome	#
The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy	392
Graves' ophthalmopathy	295
Iopanoic acid rapidly controls Type I amiodarone-induced thyrotoxicosis prior to thyroidectomy	284
Clinical and Pathological Factors Associated with Disease Persistence in Pediatric Patients with Differentiated Thyroid Carcinoma	274
Epidemiology, natural history, risk factors, and prevention of graves’ orbitopathy	273
Acquired von Willebrand syndrome in patients with overt hypothyroidism: a prospective cohort study	271
Process to radioactive iodine treatment for Graves' hyperthyroidism: condemned or absolved?	270
The phenotype of newly diagnosed Graves’ disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study	270
Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management	263
Simultaneous medullary and papillary thyroid cancer: two case reports.	262
Masked hypertension in newly diagnosed hypothyroidism: a pilot study	261
Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association	255
Cardiometabolic healthy and unhealthy obesity: does vitamin D play a role?	250
Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study	241
Breast cancer and thyroid diseases: analysis of 867 consecutive cases	241
Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves’ Disease Hyperthyroidism During Methimazole Treatment	241
The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study	239
Disease heterogeneity in IgG4-related hypophysitis: report of two histopathologically proven cases and review of the literature	238
Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European Endocrinologists	237
Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial	235
Immunomodulatory effect of vitamin D and its potential role in the prevention and treatment of thyroid autoimmunity: a narrative review	231
Irritable Bowel Syndrome with Diarrhea (IBS-D): Effects of Clostridium butyricum CBM588 Probiotic on Gastrointestinal Symptoms, Quality of Life, and Gut Microbiota in a Prospective Real-Life Interventional Study	230
Amiodarone-unduced thyrotoxicosis. A review	230
Nutrizione iodica e ipertiroidismo: quello che c’è da sapere	229
Effects of Melissa officinalis Phytosome on Sleep Quality: Results of a Prospective, Double-Blind, Placebo-Controlled, and Cross-Over Study	228
Selection, Comparative Genomics, and Potential Probiotic Features of Escherichia coli 5C, a pks-Negative Strain Isolated from Healthy Infant Donor Feces	227
Multidisciplinary Management of Intrathoracic Goiter: A Case Report	226
Features and outcome of differentiated thyroid carcinoma associated with Graves' disease: results of a large, retrospective, multicenter study	226
Continuous monitoring of the recurrent laryngeal nerve in thyroid surgery: a critical appraisal	225
Graves' hyperthyroidism of recent onset and Graves' orbitopathy: to ablate or not to ablate the thyroid?	224
Outcome prediction of treatment of Graves' hyperthyroidism with antithyroid drugs	224
Pituitary apoplexy during pregnancy: A rare, but dangerous headache	223
Can combination of glucocorticoids with other immunosoppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves' orbitopathy?	223
Arthropathy in acromegaly: a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity	223
Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves' orbitopathy: a retrospective cohort study	219
Minimally invasive follicular thyroid cancer (MIFTC) - A consensus report of the European Society of Endocrine Surgeons (ESES)	219
Can a patient-tailored treatment approach for Graves' disease reduce mortality?	219
Oral steroid prophylaxis for Graves' orbitopathy after radioactive iodine treatment for Graves' disease is not only effective, but also safe	219
Time interval in diagnosis and treatment of papillary thyroid cancer: a descriptive, retrospective study	215
Thyroid hormone treatment for differentiated thyroid carcinoma: What drug, how long, what dose?	212
Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.	210
Thyroid cancer with tracheal invasion: A pathological estimation	210
Physical performance in newly diagnosed hypothyroidism: a pilot study	208
Plasma total and acylated ghrelin concentrations in patients with clinical and subclinical thyroid dysfunction	207
Skeletal health in patients with differentiated thyroid carcinoma	206
Case report: multiple electrolyte disturbance with severe neurological manifestations induced by chronic use of PPIs	205
An update on medical management of Graves' ophthalmopathy	205
Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal	205
Characteristics of a nationwide cohort of patients presenting with isolated hypogonadotropic hypogonadism (IHH)	205
Novel treatment modalities for Graves' orbitopathy	201
Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center	200
Medullary thyroid carcinoma: surgical treatment advances	199
Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly) Italian Study Group	198
Thyroid vascularity and blood flow are not dependent on serum thyroid hormone levels:studies in vivo by color flow Doppler sonography	196
Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy	195
Medullary thyroid carcinoma: surgical treatment advances	195
Iodine supplementation in women of reproductive age: a survey of clinical practice among Italian gynecologists and midwives	194
Gastric Xanthomatous Hyperplastic Polyps – Just an Incidental Endoscopic Finding?	193
Potential pharmacological effect of Quercetin Phytosome™ in the management of hyperuricemia: results from real-life clinical studies	192
Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: Results of a prospective, single-blind, randomized study	191
Shortening Hospital Stay for Thyroid Surgery.	189
Orbital radiotherapy for Graves' ophthalmopathy	187
Severità del Morbo di Basedow di prima diagnosi: ruolo dei linfociti Treg e dei micronutrienti. Dati preliminari di uno studio osservazionale pilota	182
Analisi dei costi	181
A potential role of human RNASET2 overexpression in the pathogenesis of Graves’ disease	181
An update on the pharmacological management of hyperthyroidism due to Graves' disease	179
Vitamin D, Chronic Migraine, and Extracranial Pain: Is There a Link? Data From an Observational Study	178
Immunomodulatory role of vitamin D and selenium supplementation in newly diagnosed Graves' disease patients during methimazole treatment	178
Oxidative stress and Graves' ophthalmopathy: In vitro studies and therapeutic implications	177
Potassium perchlorate only temporarily restores euthyroidism in patients with amiodarone-induced hypothyroidism who continue amiodarone therapy	176
Relationship between management of hyperthyroidism and course of the ophthalmopathy	176
Radioiodine and thyroid-associated ophthalmopathy	175
Amyloid goiter	175
Pituitary in black—hypopituitarism secondary to hemosiderosis	174
Changes in Autonomic Modulation to the Heart and Intracellular Catecholamines. A Longitudinal Study in Differentiated Thyroid Carcinoma during Short-Term Hypothyroidism and Thyroid Hormone Replacement.	173
Effects of amiodarone, thyroid hormones and CYP2C9 and VKORC1 polymorphisms on warfarin metabolism: a review of the literature	172
Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations	171
Thyroid autoimmunity and environment	171
Amiodarone and the thyroid	171
Endpoints for screening thyroid cancer in the Republic of Korea: thyroid specialists' perspectives.	170
Effect of orally administered L. crispatus M247 in favoring HR-HPV clearance and CST shift: results from a randomized, multi-center, placebo-controlled trial	169
Cigarette smoking and treatment outcomes in Graves' ophthalmopathy	169
Treating Graves' orbitopathy: where are we?	168
Relation between Graves' orbitopathy and radioiodine therapy for hyperthyroidism: facts and unsolved questions	168
Management of thyroid eye disease	167
Orbital radiotherapy for Graves' ophthalmopathy	165
Orbital decompression in Graves' ophthalmopathy by medial and lateral wall removal	165
Novel approaches to the management of Graves' ophthalmopathy	165
Amiodarone-induced thyrotoxicosis: something new to refine the initial diagnosis?	164
Efficacy and safety of orbital radiotherapy for Graves' orbitopathy	164
Change in newly diagnosed Graves' disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression	164
Image-guided thyroid nodule ablation: technical notes and critical appraisal	163
La prevenzione dell'oftalmopatia basedowiana	161
Recent developments in the follow-up, prevention and management of complications in thyroid surgery	161
When primary hyperparathyroidism comes as good news	161
Cigarette smoking and the thyroid	159
Immunotherapy for Graves' orbitopathy: easy enthusiasm, but let's keep trying	159
Position statement of the Microbiota International Clinical Society	157
Orbital radiotherapy for Graves' ophthalmopathy	157
Prevalence and natural history of Graves' orbitopathy in the XXI century	157
Totale	20.578

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	132.845
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	132.845

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	1.395	0	0	0	71	111	139	117	88	246	291	128	204
2022/2023	2.201	272	139	170	230	158	486	16	265	264	82	52	67
2023/2024	3.560	531	536	544	653	643	333	19	41	95	46	17	102
2024/2025	2.905	14	26	435	126	100	145	135	210	306	230	366	812
2025/2026	9.719	624	737	998	1.184	800	484	1.791	581	859	637	566	458
2026/2027	3.367	581	618	1.124	1.044	0	0	0	0	0	0	0	0
Totale													31.967